免疫检查点抑制剂在抗肿瘤免疫治疗中相关预测标志物的研究进展

Research advances of predictive biomarkers for immune checkpoint inhibitors in cancer immunotherapy

  • 摘要:
    以免疫检查点抑制剂为代表的免疫疗法开创了肿瘤治疗的新时代,已在泛癌种患者中展现了持久的临床获益,但仅有一小部分患者治疗有效,且特异性的免疫相关不良事件和肿瘤超进展限制了其应用。因此开发预测性生物标志物,以筛选获益人群、最大程度降低毒性风险是目前的研究热点。本综述全面总结了免疫检查点抑制剂在抗肿瘤治疗中相关预测标志物的研究进展,并展望了它们在精准免疫治疗方面的未来方向。

     

    Abstract:
    Immune checkpoint inhibitors (ICIs)-based immunotherapy has created a new era of anti-cancer therapy and has shown durable clinical benefits in pan-cancer patients. Unfortunately, only a fraction of patients can response to ICIs. Moreover, specific immune-related adverse events and hyperprogressive diseases limit its application. Thus, it is imperative to identify valid biomarkers in optimizing patient selection for maximizing the clinical benefits and minimizing the risk of toxicity. We comprehensively summarize the current progress of predictive biomarkers for ICIs and discuss their future directions in achieving precision immuno-oncology in this review.

     

/

返回文章
返回